Compound 786
Identifiers
- Canonical SMILES:
FC(F)(F)c1nc2CN(CCc2c(NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)n1)C1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1
- IUPAC name:
N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-2-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide
- InChi:
InChI=1S/C47H50ClF6N7O5S3/c48-34-12-10-32(11-13-34)39-9-5-4-6-33(39)29-60-21-17-36(18-22-60)61-23-19-40-42(30-61)56-45(46(49,50)51)57-44(40)58-69(64,65)38-14-15-41(43(28-38)68(62,63)47(52,53)54)55-35(16-20-59-24-26-66-27-25-59)31-67-37-7-2-1-3-8-37/h1-15,28,35-36,55H,16-27,29-31H2,(H,56,57,58)/t35-/m1/s1
- InChiKey:
TZLZSMLLOXVZEI-PGUFJCEWSA-N
External links
51039625 |
External search
Bibliography (1)
Publication | Name |
---|---|
Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff, Novartis Ag. . Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer None. | 68 |
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
BCL2-Like / BAX | 6.63 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 1037.26 g/mol | |||
HBA | 12 | |||
HBD | 2 | |||
HBA + HBD | 14 | |||
AlogP | 7.95 | |||
TPSA | 137.07 | |||
RB | 17 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
WO2011029842 | 68 | BCL2 P10415 |
|
Biochemical assay | Surface Plasmon Resonance | pIC50 (half maximal inhibitory concentration, -log10) | 6.63 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.5046 | Navitoclax | DB12340 | |
0.4470 | GDC-0349 | DB13072 | |
0.3870 | Sulfaisodimidine | DB13283 | |
0.3796 | Quinupristin | DB01369 | |
0.3764 | Bleomycin | DB00290 | |
0.3742 | N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE | DB06899 | |
0.3683 | Presatovir | DB12165 | |
0.3625 | CH-5132799 | DB13051 | |
0.3589 | Sparsentan | DB12548 | |
0.3582 | Vintafolide | DB05168 | |
0.3574 | Gemigliptin | DB12412 | |
0.3551 | Omidenepag isopropyl | DB15071 | |
0.3550 | N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE | DB07800 | |
0.3525 | Sulfametomidine | DB13485 | |
0.3513 | Selatogrel | DB15163 |